Search Immortality Topics:

Page 40«..1020..39404142..5060..»


No, AI won’t steal your job. Here’s why. – ITWeb

Posted: March 25, 2020 at 10:46 am

If you dont believe our world of work is changing, you must either have your head stuck in the ground or had one too many conferences cancelled due to the coronavirus.

The platform economy is alive and well and has shaped our personal and business lives for at least the last decade. Up until recently platforms have been built on the foundation of SMAC technologies - Social, Mobile, Analytics and Cloud - and with great effect. One only has to look at the worlds most valuable companies including Apple, Amazon, Alphabet, and Alibaba. These companies have fully embraced the SMAC stack and have created levels of economic value, the like of which has seldom been seen in history.

However, change has arrived and for companies to remain competitive, SMAC no longer fits the bill.

Today, organisations are pivoting their businesses around ABEQ: artificial intelligence, blockchain (or distributed ledgers), enhanced reality and quantum computing. Of course, the most divisive of these technologies is artificial intelligence (AI).Business leaders, politicians and modern day soothsayers are all weighing in on the impact of this technology, with many believing AI will replace vast swathes of the modern workforce leaving us with a ruling elite.

One just has to look at the media to realise the state of paranoia. The percentage of jobs feared to be lost in the face of AI range from 25% to 47%. Even at the lower end, these estimates would cripple global economies and would lead to mass unemployment and potentially global unrest. However, how accurate are they?

We at Cognizants Center for the Future of Work (CFoW) believe that many of these studies fail to realise one key element that has defined all three of the last industrial revolutions. New technologies lead to new job creation. Our findings indicate that digital technologies will result in 13% new job creation, mitigating the 12% of job replacement these technologies will cause. In addition, 75% of jobs will remain but be drastically enhanced by man-machine collaboration. Yes, the disruption of these jobs will cause short- to medium-term impacts to many workers, but it is far from the doomsday scenario painted by many futurists.

The next question is: what will these new jobs be? Cognizants CFoW sought to understand exactly that and studied the latest macro, micro and socio economic trends, resulting in two report: 21 Jobs of the Future and 21 More Jobs of the Future.

These two reports name the exact jobs that will likely emerge in the future, and provide a timescale and tech centricity of when and how these jobs will occur. Spoiler: not all jobs of the future will require massive technical expertise. Instead, jobs will pivot around three core pillars that are currently shaping modern society: coaching, caring and connecting.

Heres why:

Ultimately, it is very easy to be caught up in the dystopian fear of the unknown future. However, instead we need to have a fascination with the unknown.

About the authorMicheal Cook is senior manager responsible for developing thought leadership in Cognizants EMEA Center for the Future of Work - a fulltime think tank of Cognizant Technical Services. Now based in London, Michael was born in Johannesburg and earned his Bachelors of Economics and Econometrics and Post Graduate qualification of International Trade and Development from the University of Johannesburg.

See the original post:
No, AI won't steal your job. Here's why. - ITWeb

Recommendation and review posted by Ashlie Lopez

IIT Guwahati researchers working to develop coronavirus vaccine! – Northeast Now

Posted: March 25, 2020 at 10:45 am

While the world is facing a major crisis due to the coronavirus (COVID-19) outbreak, the IIT Guwahati researchers are working to develop a vaccine to provide an active acquired immunity to the infectious disease.

A media report said the Indian Institute of Technology (IIT), Guwahati is also making efforts to develop rapid detection and portable diagnostic kits for various viruses and microorganisms.

The group of IIT Guwahati researchers has been led by Prof Sachin Kumar of the Department of Biosciences and Bioengineering.

The report quoted the institute as informing that to find a solution for the diseases, its researchers are exploring possibilities to clone the immunogenic proteins of SARS-CoV-2 to be used as diagnostics and possible vaccine candidates.

COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Meanwhile, to prevent the spread of the virus, the institute has also developed the prototype of a Faceshield or mask as per the guideline of the World Health Organisation (WHO).

The team has been led by Dr. Supradip Das of the Department of Design.

Informing about this, the IIT Guwahati on its Twitter handle said: @IITGuwahati has developed the prototype of a Faceshield as per the guideline of the @WHO to be used along with other Personal protective equipment. Faculty has plans to #3Dprint up to 100 pieces. congratulations to Dr. Supradip Das, AP, DoD.

According to the media report, IIT Guwahati has also developed hand-sanitisers as prescribed by the WHO and these are being distributed to everyone on the campus of the institute, including visitors.

The researchers group of the Department of Biosciences and Bioengineering in IIT Guwahati earlier developed recombinant vaccines against Japanese encephalitis and classical swine fever virus.

The research was published in the journal Vaccine and Archives of Virology.

Go here to see the original:
IIT Guwahati researchers working to develop coronavirus vaccine! - Northeast Now

Recommendation and review posted by G. Smith

Walking Sticks Stop, Drop and Clone to Survive – KQED

Posted: March 25, 2020 at 10:45 am

Fortunately, the unusual insects, who live on every continent except Antarctica, are readily available as subjects.

"It's a very prevalent invasive species that can be found all throughout California, including right here on campus, Ramirez said. "All of our specimens we study were collected when they're out and about at night around the nearby creek, since they're nocturnal."

Colors are an important part of a stick insects camouflage defense. When these stick insects first hatch, theyre brown. As they mature and go through successive molts, they may change to an array of vibrant colors from light green to a much darker brown.

"Having adults in a variety of colors allows them to occupy and better survive in different parts of a plant, Ramirez said. "Having a darker stick insect may allow it to blend in more with the trunk of a tree or the darker stems of ivy and blackberry. On the other hand, lighter green stick insects have an advantage on greener surfaces such as the bottom of leaves or greener stems of plants."

These differences in color also affect how well they can escape predators. A darker stick insect can use another means of defense behavioral mimicry if it feels threatened. Once it tucks in its limbs, itll fall down to the ground and "look like a dead twig," Ramirez said.

One puzzle Ramirez is trying to solve is why theres such a colorful palette of Indian walking sticks. Theyre parthenogenic, which means the females dont need males to reproduce. They can actually clone themselves.

"So to see a wide variety of different colors in the stick insects is very interesting because if they're clones of the mother they should all be the same exact thing, but they're not," he said.

"That's something that's really interesting to explore and would definitely require more genetic analysis, which we haven't gotten to quite yet. But hopefully someday that'll be possible in the future," he added.

One reason could be due to genetic mutations.

"There are plenty of other species that undergo parthenogenesis such as aphids, species of bees, ants, wasps, flies, and others which all go through similar asexual cloning mechanisms and can have mutations," Ramirez said. "However, these insects contain very little or do not have any noticeable color variation compared to the Indian stick insects."

Ramirez said he hopes to use the CRISPR/Cas9 gene editing tool to try and unlock the mysteries behind the Indian walking stick.

Hes also planning to apply to dental school after he graduates later this year, with the goal of using what hes learned studying walking sticks. His background in genetics and gene editing will help him in emerging fields of research, such as bioengineering human teeth using stem cells.

"This would be revolutionary for dentistry as patients who have lost their permanent teeth could have them replaced," Ramirez said.

See original here:
Walking Sticks Stop, Drop and Clone to Survive - KQED

Recommendation and review posted by G. Smith

Visiongain Report Looks at Opportunities Within the $23bn Cell Therapy Technologies Market – PR Newswire UK

Posted: March 25, 2020 at 10:45 am

Cell Therapy Technologies Market Forecast 2020-2030

LONDON, March 25, 2020 /PRNewswire/ -- Consumables, Equipment, System & Software, Cell Processing, Cell Processing Equipment, Single Use Equipment, Cell Preservation, Distribution, Handling, Process Monitoring & Quality Control, Human Cells, Animal Cells, Life Sciences & Research Companies, Research Institutes

Visiongain estimates that the global cell therapy technologies market will grow at a CAGR of 15% in the first half of the forecast period. In 2020, North America is estimated to hold 38% of the global cell therapy technologies market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new201-page reportyou will receive104 tables and 110 figures all unavailable elsewhere.

The 201-page Visiongain report provides clear detailed insight into the cell therapy technologies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/cell-therapy-technologies-market-forecast-2020-2030/#download_sampe_div

Report Scope

Global Cell Therapy Technologies Marketfrom2020-2030

Forecast of the Global Cell Therapy Technologies Market byType of Product: Consumables Equipment:Cell Processing Equipment, Single Use Equipment, Other Equipment System & Software

Forecast of the Global Cell Therapy Technologies byProcess Type: Cell processing Cell preservation, distribution and handling Process monitoring and quality control

Forecast of the Global Cell Therapy Technologies byCell Type: Human cells:Stem cells, Differentiated cells Animal cells

Forecast of the Global Cell Therapy Technologies byEnd User: Life Sciences and Research Companies Research Institutes

This report provides individual revenue forecasts to 2030 for thesenational markets: The US Canada Mexico UK Germany France Italy Spain Japan China India South Korea Singapore Malaysia Russia Brazil Argentina UAE South Africa Nigeria Mexico

Our study discusses the selectedleading companiesthat are the major players in the respiratory inhalers market: GE Healthcare Lonza Group Merck KGaA Terumo Bct, Inc. Thermo Fisher Scientific, Inc. & Other Companies

For the leading companies, we feature product portfolios, business segment breakdowns, recent developments & key expansion strategies etc.

This report discussesfactors that drive and restrainthis market. As well asopportunitiesandchallengesfaced by this market.

This report discusses thePorter's Five Forces Analysisof the Cell Therapy Technologies Market.

Key questions answered by this report: How is the Cell Therapy Technologies Market evolving? What is driving and restraining factors of the Cell Therapy Technologies Market? What are the market shares of each segment of the overall Cell Therapy Technologies Market in 2020? How will each Cell Therapy Technologies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030? How will the market shares for each Cell Therapy Technologies submarket develop from 2021 to 2030? What will be the main driver for the overall market from 2021 to 2030? Will leading national Cell Therapy Technologies Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others? How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030? Who are the leading players and what are their prospects over the forecast period? How will the industry evolve during the period between 2020 and 2030?

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/cell-therapy-technologies-market-forecast-2020-2030/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.comto discuss any customized research needs you may have.

Companies covered in the report include:

Affymetrix, Inc.AkouosAllCellsApplikon Biotechnology Inc.ATLATL CentreAutolus LimitedBeckman Coulter, Inc.Becton, Dickinson and CompanyBioengineering AGBiological IndustriesBioWa, IncBrammer BioC.R. Bard, Inc.CaridianBCT, IncCell and Gene Therapy Asia Technology CentreCentre for Process Innovation (CPI)CMC Biologics (Asahi Glass Co.)Cobra BiologicsCocoon PlatformCryoportDanaher CorporationDiNAQOR AGEMD Performance MaterialsEMD SeronoEppendorf AGEuropean Molecular Biology Laboratory (EMBL)Finesse Solutions, Inc.Flexsafe RM TXFloDesign SonicsFlowJo, LLCFood and Drug Administration (FDA)Gamida CellG-CON ManufacturingGE healthcareGenScriptInfors HTIntegrated DNA Technologies, Inc.LaVision BioTecLonza Group, GE HealthcareMassachusetts Eye and Ear (MEE)Meissner Filtration Products, Inc.Merck KGaAMerck SeronoMesoblastMilliporeSigmaMiltenyi BiotecNova BiomedicalPall Corporation (Pall)Patheon N.V.Penn State UniversityPharmaCell B.VSartorius AGSartorius Stedim BiotechScinogySelecta Biosciences, IncSiemensSolaris BiotechStafa Cellular TherapyStafaCTStemcell TechnologiesTerumo Bct, Inc. (A Subsidiary of Terumo Corporation)Thermo Fisher Scientific, Inc.Tillotts Pharma AGTranstem LabUniCAR TherapyWorld Courier

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Global Stem Cell Technologies and Applications Market 2019-2029

Biobanking Market Forecasts 2019-2029

Biologics Market Trends and Forecasts 2019-2029

Global Bioreactors Market 2020-2030

Global Precision Medicine Market Forecast 2019-2029

Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

SOURCE Visiongain

See original here:
Visiongain Report Looks at Opportunities Within the $23bn Cell Therapy Technologies Market - PR Newswire UK

Recommendation and review posted by G. Smith

TCR therapy an attractive alternative to CAR T for immunotherapy – Drug Target Review

Posted: March 25, 2020 at 10:45 am

Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process and explains why he is excited about seeing an idea translate into an industrial proposition.

STIMULATING the natural defences of a persons immune system to kill cancer cells, known as immunotherapy, has become a novel and exciting approach to treat cancer. For example, the role of T cells in cell-mediated immunity has inspired the development of several strategies to genetically modify T cells, such as chimeric antigen receptor (CAR) T-cell therapy, to target cancer cells. In recent years, CAR T-cell therapy has received much attention from researchers and the press alike, and the landmark approval and clinical successes of Novartis Kymriah (the first FDA-approved treatment to include a gene therapy step in the United States) and Gilead/Kite Pharmas Yescarta (the first CAR T-cell therapy for adults living with certain types of non-Hodgkin lymphoma) has prompted a surge of further research. However, this approach which involves isolating cells from a patient, bioengineering them to express CARs that identify and attach to tumour cells and injecting them back into the patient has several limitations, according to Miguel Forte, former CEO of Zelluna Immunotherapy and currently CEO of Bone Therapeutics.

Forte has been working on a T-cell immunotherapy approach that primarily focuses on the T-cell receptors (TCRs). Similar to CAR therapies, TCR therapies modify the patients T lymphocytes ex vivo before being injected back into the patients body. However, they differ in their mechanisms for recognising antigens. CAR T-cell therapy can be compared to a policeman, with a photograph of the criminal, being able to identify them on the street, explained Forte. It is an artificial way of guiding those cells to the cancer when the cancer cells are in suspension. The difficulty with CAR is that it cannot always penetrate and deliver an effect in solid tumours. TCR therapy, which utilises the natural mechanisms that T cells use to recognise the antigen and therefore the cancer, is better suited to penetrate the tumour ie, the policeman is able to go inside the building where a criminal is hiding.

It is obviously more costly at the beginning of the development when you are fine tuning your process, compared to when you progress to a larger scale as you approach the market

Of note, this approach targets the TCR- peptide/major histocompatibility complex (MHC) interaction, which enables eradication of tumour cells. Intracellular tumour-related antigens can be presented as peptides in the MHC on the cell surface, which interact with the TCR on antigen-specific T cells to stimulate an anti-tumour response. Imagine you, or the cells, are not just a soldier in an army but a captain that can bring other immune cells into the mix. TCRs and these cells, once they go in, have a direct kill activity and an immunostimulatory activity to other cells to have a more comprehensive effect of killing the tumour cells. Forte concluded that this approach is scientifically appealing and could bring value to a large array of solid tumours.

The benefits of TCR therapies are evident; however, as with all new approaches, it is not without its challenges. The first relates to the manufacturing of these therapies; the process requires extracting patient material, changing it and then returning it to the patient. Unlike drug discovery with small molecules where you have an inert, well-defined, chemically-established component, with biologics you go up a notch in terms of complexity, Forte explained, adding that while small molecules are unidimensional, biologics are three-dimensional and, thus, more complex and challenging to manufacture. You need to remember that your product, the cells, are a living being. It is something that replicates, changes and responds to its environment. This makes it a lot more challenging to characterise and define the right specifications of the product. The initial challenge is to put in place a consistent and reliable manufacturing process.

Generating the necessary pre-clinical data can also prove challenging; studies are easier to conduct in animal models when you are working with chemical entities rather than human cells, according to Forte. Finally, when the product does get to clinic, there are elements of manufacturing, supply and logistics that can prove challenging; however, companies are starting to provide solutions for this. Working in cell and gene therapy we need to apply what we have done with other products, explained Forte. You need to adapt to the complexity and diversity of the product you have in hand. Here, you have a live product. Something that responds. It is similar to having a child; you can modulate it, but you can never fully control the behaviour of something you are shaping.

Bringing a new drug to market, from drug discovery through clinical trials to approval, can be a costly process, especially when developing cell-based therapies. These are more expensive than developing chemistry or biologics, but when biologics started to be developed, they were also very expensive, explained Forte. We are now seeing a reduction of those costs as more companies are developing products and consequently more solutions are surfacing.

Forte was involved in developing his first cell therapy product about 10 years ago. At this time, it was difficult; a lot of solutions you had to build in house. Nowadays, you can import this from solutions already available so you can concentrate on the specificity; for instance, the viral vector for gene editing your cells or the cytokine concentration for the expansion of your cells. He added that as these therapies grow, so too does the competition, resulting in reduced costs. However, the price and return on investment must correlate with benefit. It is obviously more costly at the beginning of the development when you are fine tuning your process, compared to when you progress to a larger scale as you approach the market.

The well-publicised success story of Emily Whitehead a six-year-old leukaemia patient who was one of the first patients to receive CAR T-cell therapy is a prime example of the success of immunotherapy treatments. Even though these patients may need to continue medications, they can live a relatively normal life. The gene- edited cells remain in the individual and continue to control the cancer by restoring the immune systems capabilities, said Forte. He hopes that similar results will be seen with TCR therapies: Hopefully, a significant fraction of patients will have a clinical and biological response that will reduce the tumour bulk, give them a quality life and remain doing so by controlling the cancer for a significant amount of time.

Forte concluded that the possibilities for TCR- based immunotherapies are exciting and hopefully products will be developed that will deliver an immediate and sustained effect in cancer patients.

About the author

MIGUEL FORTE

Miguel is currently the CEO of Bone Therapeutics and visiting Professor at the Lisbon University in Portugal. He also serves as Chief Commercialization Officer and Chair of the Commercialization Committee of the International Society of Cellular Therapy (ISCT) and is Member of Board of Directors of ISCT and ARM. Miguel was CEO of Zelluna Immunotherapy until the end of 2019. Miguel holds a masters degree from the Faculty of Medicine of the University of Lisbon, Portugal, a PhD in Immunology from the University of Birmingham, UK, an accreditation as Specialist in Infectious Diseases and a certificate on Health Economics of Pharmaceuticals and Medical Technologies (HEP). He is Fellow of the Faculty of Pharmaceutical Medicine of the RCP in the UK.

See the article here:
TCR therapy an attractive alternative to CAR T for immunotherapy - Drug Target Review

Recommendation and review posted by G. Smith

SwRI Receives $9.9 Million to Develop Nerve Agent Antidote – Business Wire

Posted: March 25, 2020 at 10:45 am

SAN ANTONIO--(BUSINESS WIRE)--Southwest Research Institute has received funding from the Medical CBRN Defense Consortium (MCDC) administered by Advanced Technology International to develop a nerve agent antidote for emergency use on the battlefield or to protect public health.

The use of nerve agents continues to be a significant threat to both military and civilian populations. This prototype medication could serve as a countermeasure against a nerve agent attack. SwRI will lead the development of the antidote under the $9.9 million, five-year program, and will collaborate with University of Pittsburgh on the synthesis and compound design, through the support of the Defense Threat Reduction Agency (DTRA).

This antidote improves on the current standard of care, importantly, its ability to reverse the effects of the toxin in the central nervous system, said SwRIs Dr. Jonathan Bohmann, a principal scientist in SwRIs Pharmaceutical and Bioengineering Department. The antidote will eventually be administered through an autoinjector, which allows for rapid and effective treatment in the field. It would work much like an Epinephrine Auto-Injector or EpiPen administered during a severe allergy attack. The initial goal of the project is to support our warfighters; however, this treatment could also eventually be administered for civilian use.

In the design of the new medication, SwRI will use a computer-based drug design software platform called Rhodium. SwRI developed Rhodium, a proprietary docking simulation software program tool, to enhance drug design and safety while reducing costs and speeding up development time. The Institute offers Rhodium as a service to clients.

SwRI is one of 193 industry, government and nonprofit organizations supporting the medical countermeasures sector in MCDC. This sector was founded to support U.S. Department of Defense needs in areas of infectious diseases, chemical threats and other medical countermeasures for military personnel.

SwRIs Chemistry and Chemical Engineering Division is ISO 9001:2015 certified, meeting international quality standards for product development from initial design through production and service. SwRI scientists support drug development from discovery to clinical trials in FDA-inspected Current Good Manufacturing Practice facilities.

Rhodium supports drug development and screening for antibiotics as well as preventative treatments such as vaccines. The software also predicts adverse drug reactions and side effects.

For more information, visit https://www.swri.org/industries/pharmaceutical-development.

https://www.swri.org/press-release/rhodium-nerve-agent-antidote-dtra-mcdc

See the original post here:
SwRI Receives $9.9 Million to Develop Nerve Agent Antidote - Business Wire

Recommendation and review posted by G. Smith


Page 40«..1020..39404142..5060..»